Introduction
The skin is used as route of drug administration both for compounds intended as topical treatments and for those intended as systemic treatments where there is a requirement to avoid the first pass effect. 1 Since there are issues in reliably obtaining human skin for pre-clinical studies (and sufficient skin for a representative study given issues including, race, gender, age and genetic polymorphisms) there is a great deal of interest in the use of 3D in vitro tissue engineered models of human skin as reproducible and easy to obtain testing platforms. 1 In a recent review by Mathes et al. the use of these models in drug development has been described. 2 Skin models commercially available include: human reconstructed epidermis (HRE), 3D differentiated epidermis cultures derived from human keratinocytes, i.e. EpiSkin (Epskin, Lyon, France) and EpiDerm (Mattek, Ashland USA) and full thickness living skin equivalents (LSE) e.g. EpiDermFT (Mattek Ashland USA), T-skin (Episkin, Lyon, France) and Labskin (Innovenn(UK) Ltd York UK). 3 Mass spectrometry imaging (MSI) is a relatively new and powerful technique able to study intact tissue sections providing ion distribution maps of many non-labelled endogenous and exogenous species simultaneously. This is a distinct advantage in comparison to conventional techniques, such as immunohistochemistry and radiolabelling. The absence of the label makes this technique fast, relatively inexpensive. It has been used extensively in studies of pharmaceutical distribution 4 and its use to study skin absorption was one of the first applications of MSI in pharmaceutical analysis to be reported. 5 The application of mass spectrometry imaging (MSI) to 3D in vitro tissue models of human skin represents a valid approach for investigating either drug absorption or drug biotransformation in skin. Arvey et al. 6 were the first to combine MSI with a comercially available 3D tissue model of the epidermis "Straticel" in order to analyse the penetration of the drug imipramine. In later work conducted by Francese et al. 7 and Mitchell et al. 8 full thickness living skin equivalents (LSEs) were used as models to be analysed by MALDI-MSI. Such models consist of a full differentiated epidermal layer supported by a dermal component generated by seeding fibroblasts into a 3D
scaffold. The aim of the work reported by Francese et al. 7 was to evaluate the efficiency of curcumin as a MALDI matrix. After the application of this matrix, MALDI-MSI was used to plot the localization of the drug acetretin within Labskin, a commercial living skin equivalent model. This study demonstrated that at 4 hours post treatment the drug had penetrated into the epidermal layer. In a more recent work, Harvey et al. 9 used MALDI-MSI to map the same drug acetrin in Labskin models, in which psoriasis was induced by treating the samples with the proinflammatory cytokine interleukin-22. This study showed that at 24 hours post treatment the drug was localised onto the epidermal layer, whereas after 48 hours the drug had penetrated into the dermal region. 9 Such studies have demonstrated that the widespread adoption of MSI in skin research could contribute to the study of drug/toxicant absorption, drug/toxicant response, infection, would-healing and burns.
In MALDI-MSI the nature of analyte ionization depends strongly on the entity of the analyte as well as the tissue. The same molecule can be subjected to varying ion suppression effects in different tissues or across the same tissue in response to a changeable histological framework as well as to the ionization competition with compounds within the morphological microenviroment. 10 This aspect in addition to the variation of ion signals due to heterogeneity of matrix deposition represent the major issues that need to be addressed in the development MALDI-MSI as a method for quantitative mass spectrometry imaging (QMSI Labskin living skin equivalent (LSE) samples were provided by Innovenn (UK) Ltd (York, England).
ii. Sample treatment Living skin equivalent (LSE) samples were obtained at day 7 air liquid interface (ALI) and incubated in Labskin maintenance media for 24 hours within 5% CO 2 at 37°C. Before matrix application and imaging the samples were freeze-dried under vacuum (0.035 mBar) for 2 hours to avoid delocalization of the analyte and preserve the integrity of the tissues.
iii. Preparation of Standard Curves
For MALDI-MSI experiments, working standards were made to 0.01, 0.1, 1, 10, 100, 500, 1000 and 1500 ng/µL of TBF HCl with 100 ng/µL of the internal standard TBF d7 HCl in MeOH/H 2 O (50:50).
Calibration standards were applied onto the epidermis area of 12 µm thick sections of blank tissue sections using an acoustic robotic spotter (Portrait 630, Labcyte Inc., Sunnyvale, CA). The experimental instrument parameters used were: capillary voltage: 3.0kV, cone voltage: 35.0V, source temperature: 140°C, desolvation temperature: 250°C, desolvation gas:1000L/hr and cone gas: 50L/hr.
Argon was utilized as collision gas and the collision energy was set at 19eV.
A multiple reaction monitoring (MRM) method was used to detect the product ion of Terbinafine 
vii. Skin extraction
The vehicle control and treated Labskin tissues were placed for 2 min in 1X PBS pre-heated at 60°C; then, the epidermis was separated from the dermis by using forceps, transferred to tubes and weighted.
The tissue homogenisation and drug extraction were performed by a small modification of previously published work carried out by Sachdeva et al. 21 The modification made was that after the second extraction, the back extraction was not performed; instead, the organic layer containing the extracted drug was evaporated under nitrogen and, then reconstituted in 1. viii. Histological Staning LSE sections were stained used Mayer's haematoxylin and eosin solutions. Each slide was rehydrated by submerging in 100%, 95% and 70% EtOH washes for 3 min and they were left for 1 min in deionised water before being stained in filtered Meyer's haematoxylin for 10 min. Tissues were washed in running tap water for 3-5 min and dehydrated using 70% and 95% EtOH solutions and immersed in filtered eosin 100% for 1 min. The last dehydration step was performed using 95% and 100% EtOH solution, each for a period of 3 min. Finally, the slides were submerged in 2 changes of xylene substitute for 5 min each and mounted using Pertex mountant.
Optical images were obtained using a Cytation 5 imaging reader and analysed with Gen5 software (BioTek, Swindon, UK).
ix. Data Analysis MALDI-MSI data were processed using the HDI 1.4 (Waters Corporation, UK) software tool.
Using this software, MSI raw data files were converted in imzML format and imported into MSIQuant software for quantitative investigations.
For LC/MS/MS data, the chromatograms peaks for Terbinafine hydrochloride and Terbinafine d7
hydrochloride were integrated and processed using Mass Lynx (Waters Corporation, UK) software tool.
Statistical analysis was performed using the StatDirectsoftware (StatsDirect, Cheshire, UK). F test and T test were used to evaluate the statistical significance in terms of precision and accuracy, respectively, between the values obtained by MALDI-MSI and LC/MS/MS techniques.
Three replicate measurements (n=3) were used and the level of significance was set to 5%.
Outlier point identifications were performed using Prism software. The method selected was
Grubbs' test for outliers (α= 0.05).
Results and Discussion
Reproducibility of droplet spot size of the Portrait 630.
Manually spotting of calibrants onto control tissues has constituted one of the major approaches for generating calibration array in previous QMSI experiments. 13, [22] [23] [24] Although widely practiced, this technique is not without limitations. One of the major drawbacks of manual pipetting is the difficulty of depositing sub-microliter volumes of solutions. This makes it difficult to localize standards to small defined regions of tissue. Furthermore, manually applied spots are susceptible to variations in size and, hence, the amount standards in the spots are difficult to control.
In this study we decided to measure and compare the perimeter and area of the droplet spots generated by the Portrait 630 in order to assess the reproducility and accuracy of this device. In 
Method used for quantitation
In MALDI-MSI, the optimisation of the matrix disposition method is an essential pre-requisite for reproducible detection of the analyte of interest with the required sensitivity and spatial resolution.
In previous work 25 we have reported that matrix sublimation 26 is an excellent methodology for the production of high resolution images of xenobiotic distribution in skin and 3D skin models. hours. It can be seen that the Terbinafine signal appears to be localized to the epidermis and that there is an increase in its intensity with increasing amount of DMI.
In order to quantify the amount of Terbinafine in the epidermis from such images it is necessary to calibrate the response specifically for signals arising from the epidermis to achieve "matrix matched standards". Previous studies have shown that the epidermis of Labksin consists of a very thin differentiated layer with an average thickness of 32 µm. 9, 27 As discussed previously, this makes preparing standards by tissue spotting challenging. Therefore in this work, the use of an acoustic picoliter droplet ejector, used previously as a MALDI matrix deposition device, 16 signal ion reproducibility and image quality due to an increase of pixel to pixel precision. 14, 15 Therefore, it was decided to use a deuterated analogue of Terbinafine hydrochloride with seven deuterium ions on naphtalene group in order to distinguish the fragment ion of the internal standard to the fragment ion of the analyte in the mass spectrum, leading an increase of selectivety.
Different approaches for applying a constant concentration of internal standard uniformly to the tissue have been investigated. Most commonly, an automatic spray-coating device is implied to deposit an internal standard either premixed with MALDI matrix 13, 24, 30 or prior to matrix deposition [31] [32] [33] onto the tissue. Instead, we found it beneficial to apply the internal standard onto the tissue by microspotting in order to preserve the localization of the calibration analyte, which, instead it was found to migrate when the solution of Terbinafine d7 hydrochloride was sprayed onto the tissue (data not shown). In agreement with previous studies, we found that the normalisation of the analyte signal to its deuterated analogue caused a significant improvement in the calibration curve linearity with a correlation coefficient (R 2 ) from 0.9968 to 0.9992 upon normalisation. The limits of detection (LOD) and quantitation (LOQ) were calculated; from these calibration data: the LOD was found to be 1.30 ng/mm 2 or 0.11 mg/g tissue, whereas, LOQ was found to be 3.93 ng/mm 2 or 0.33 mg/g tissue.
Quantitation of the drug within the tissue. As shown in Figure 4D , in initial experiments the apparent levels of the drug were found to be 0.15 ± 0.11 mg/g tissue in vehicle control, 0.35 ± 0.047 mg/g tissue within Labskin treated with
Terbinafine at 10% DMI, and, 0.84 ± 0.14 mg/g tissue within Labskin treated with Terbinafine at 50% DMI. On investigation it was found that the internal standard solution used contained a small amount of the unlabelled drug. The problem related to deuterium-hydrogen exchange in deuterated compounds was previously described by Chavez et al. 34 and can lead to an overestimation of the concentration of unlabelled analyte. To correct for this the amount of Terbinafine detected in the vehicle control was subtracted from the amount of Terbinafine detected in the treated tissues for each QMSI experiment. After this correction, at 10% DMI the concentration of TBF was found to be 0.20 ± 0.072 mg/g of tissue (below the formal limit of quantitation), and at 50% DMI the level was found to be 0.69 ± 0.23 mg/g tissue.
In order to validate the MALDI-MSI data LC/MS/MS experiments were performed using the methodology described by Sachdeva et al. 21 LC/MS/MS is a high sensitivity technique, widely used in previous studies for quantification of Terbinafine hydrochloride. 35, 36 Although it is common knowledge that LC/MS/MS provides reliable quantitation, analysis using this technique can not be carried out directly on the intact surface skin, but analytes of interest have to be extracted out of the tissue, increasing the complexity of sample preparation, time of analysis and losing spatial information. In addition, another drawback on using LC/MS/MS is represented by the amount of tissue necessary for homogenization (from 0.5 mg to 50 mg) compared to the small amount of tissue that can be analysed using MALDI-MSI (0.010-0.012 mg).
LC/MS/MS experiment was repeated three times per each tissue of Labskin and the limit of detection (LOD) and quantitation (LOQ) were assessed at 0.42 µg/mL and 1.27 µg/mL, respectively. In the vehicle control sample, the levels of Terbinafine were below the limit of detection, whereas, at 10% DMI and 50% DMI the levels were above the LOQ and they were found to be 0.28 ± 0.040 mg/g tissue and 0.66 ± 0.057 mg/g tissue, respectively.
A statistical unpaired T test was perfomed on the data from both tissues treated with Terbinafine with either 10% DMI or 50% DMI. The concentration of the drug resulted statistically increased in the tissue when the percentage of DMI increased in the formulation in both QMSI (two sided P= 0.0256) and LC/MS/MS (two sided P= 0.0007) ( Figure 4E-F Figure 4G ).
These data have demonstrated the development of a QMSI method for the determination of the amount of an active pharmaceutical ingredient in skin. In addition the capability of the penetration enhancer DMI to increasing the drug penetration in the upper epidermis of living skin equivalent has been demonstrated.
Conclusions
In Figure S1 (A-C) data from measurement of spot size reproducbility experiments. 
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